We’re excited to attend and cover FutureMed next week, from May 10th to May 15th. For those who haven’t heard of it, FutureMed is a medical-focused executive program from Singularity University, a Silicon Valley institution for studying and capitalizing on exponentially advancing technologies (see our previous post, here).
We’ll be staying on site at the NASA-Ames research center and doing our best to cover as much of the event as possible. The program is exceedingly dense (with 8am – 10pm days), so we’d love your thoughts on what you’d like us to focus on. Take a look at the schedule and program tracks (also below), and let us know in the comments what interests you.
Tracks include (from the FutureMed website):
1. Information – Data driven health: Digitization of healthcare, Electronic health records, Imaging Technology, Wearable devices, Wireless monitoring to ubiquitous Apps. The data explosion… from Imaging & Diagnostics to Mobile & Internet Enabled Health… Knowledge liquidity and leveraging information to enhance diagnostics, prevention and therapy
2. Personalized Health & ‘Omics’: Low cost, point of care Genomics, Proteomics, Metabolomics, the Environmental monitoring… Systems medicine & biology to the rapidly emerging world of Synthetic Biology and DIY Biology.
3. Regenerative Medicine: Stem cells & beyond for the repair, replacement and regeneration of tissues and organs damaged by aging, trauma or disease, from cell therapy to limb regeneration. Cellular alchemy (reprogramming skin cell to cardiomyocytes) to 3-D printing of organs and tissues.
4. Intervention: From Robotic Surgery, Bionic limbs and exoskeletons, Smart pills, and Implantable Devices, to targeted gene therapy, and ever shrinking and more capable devices, Nanomedicine.
5. Neuromedicine: Real time brain imaging, Brain computer interface (BCI), Cognitive Enhancement, Targeted neurointervention, Psychiatry and Behavioral Medicine.
6. Medtech/Biotech & Entrepreneurship: Includes Synthetic Biology, Future of Drug Discovery, Device Development and the funding, opportunities and barriers (regulatory and otherwise) of biomedical innovation. Drive to lower costs and more effective therapies.